Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2024ACS Infectious DiseasesOpen Access

Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMary NantongoDNDavid C. NguyenCBChristopher R. Bethel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nantongo et al. (2024) studied this question.

synapsesocial.com/papers/68e6f15ab6db64358766b904https://doi.org/10.1021/acsinfecdis.4c00119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Novel Peptidoglycan Cross-linking Enzyme for a β-Lactam-resistant Transpeptidation Pathway2005 · 236 citations
  2. 2Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?1995 · 202 citations
  3. 3Inactivation of Mycobacterium tuberculosis l , d -Transpeptidase Ldt Mt1 by Carbapenems and Cephalosporins2012 · 156 citations
  4. 4Molecular Basis of Class A β-Lactamase Inhibition by Relebactam2019 · 87 citations
  5. 5Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations2013 · 45 citations